HRP20201307T1 - Upotreba reslizumaba za liječenje umjerene do ozbiljne eozinofilne astme - Google Patents
Upotreba reslizumaba za liječenje umjerene do ozbiljne eozinofilne astme Download PDFInfo
- Publication number
- HRP20201307T1 HRP20201307T1 HRP20201307TT HRP20201307T HRP20201307T1 HR P20201307 T1 HRP20201307 T1 HR P20201307T1 HR P20201307T T HRP20201307T T HR P20201307TT HR P20201307 T HRP20201307 T HR P20201307T HR P20201307 T1 HRP20201307 T1 HR P20201307T1
- Authority
- HR
- Croatia
- Prior art keywords
- reslizumab
- patient
- inhaled corticosteroid
- eosinophilic asthma
- asthma
- Prior art date
Links
- 229960003254 reslizumab Drugs 0.000 title claims 4
- 208000006673 asthma Diseases 0.000 title claims 3
- 239000003246 corticosteroid Substances 0.000 claims 4
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 claims 2
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 claims 2
- 229960002714 fluticasone Drugs 0.000 claims 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 229960003728 ciclesonide Drugs 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 229940124625 intravenous corticosteroids Drugs 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Claims (2)
1. Reslizumab za upotrebu u liječenju eozinofilne astme, pri čemu:
3 mg/kg reslizumaba se primjenjuje intravenski jednom svakih 4 tjedna pacijentu zajedno s dugo djelujućim agonistom adrenoceptora beta (LABA) inhalacijskim kortikosteroidom, te inhalacijski kortikosteroid sadrži > 500 µg flutikazona, > 440 µg mometazona, > 800 µg budezonida, > 320 µg ciklezonida, > 400 µg beklometazona, ili > 2000 µg triamcinolona, navedeni pacijent ima razinu eozinofila u krvi jednaku ili veću od 400/µl, a prije upotrebe, pacijentovi simptomi su bili neadekvatno kontrolirani navedenim djelujućim agonistom adrenoceptora beta (LABA) i inhalacijskim kortikosteroidom i
pri čemu, je tijekom 12 mjeseci prije upotrebe pacijent imao najmanje jedno pogoršanje astme koja je zahtijevala oralnu, intramuskularnu, ili intravensku primjenu kortikosteroida tijekom dulje ili jednako 3 dana.
2. Reslizumab za upotrebu u skladu s patentnim zahtjevom 1, naznačen time što je inhalacijski kortikosteroid > 500 µg flutikazona.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047248P | 2014-09-08 | 2014-09-08 | |
| US201462091150P | 2014-12-12 | 2014-12-12 | |
| US201562168007P | 2015-05-29 | 2015-05-29 | |
| US201562191690P | 2015-07-13 | 2015-07-13 | |
| PCT/US2015/047357 WO2016040007A1 (en) | 2014-09-08 | 2015-08-28 | Use of reslizumab to treat moderate to severe eosinophilic asthma |
| EP15760590.8A EP3191513B1 (en) | 2014-09-08 | 2015-08-28 | Use of reslizumab to treat moderate to severe eosinophilic asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201307T1 true HRP20201307T1 (hr) | 2020-11-27 |
Family
ID=54066234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201307TT HRP20201307T1 (hr) | 2014-09-08 | 2020-08-20 | Upotreba reslizumaba za liječenje umjerene do ozbiljne eozinofilne astme |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9815894B2 (hr) |
| EP (1) | EP3191513B1 (hr) |
| KR (1) | KR102495432B1 (hr) |
| CN (1) | CN107073114B (hr) |
| AU (1) | AU2015315628A1 (hr) |
| CA (1) | CA2962944A1 (hr) |
| CY (1) | CY1123501T1 (hr) |
| DK (1) | DK3191513T3 (hr) |
| EA (1) | EA034864B1 (hr) |
| ES (1) | ES2811124T3 (hr) |
| HR (1) | HRP20201307T1 (hr) |
| HU (1) | HUE050202T2 (hr) |
| PL (1) | PL3191513T3 (hr) |
| PT (1) | PT3191513T (hr) |
| RS (1) | RS60701B1 (hr) |
| SI (1) | SI3191513T1 (hr) |
| UA (1) | UA122670C2 (hr) |
| WO (1) | WO2016040007A1 (hr) |
| ZA (1) | ZA201702247B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180056018A1 (en) * | 2016-08-31 | 2018-03-01 | Cephalon, Inc. | Inhalation Systems, Devices and Methods |
| EP3634434A4 (en) * | 2017-05-12 | 2021-06-09 | The Regents of The University of California | TREATMENT AND DETECTION OF DYSBIOSIS |
| JP7307720B2 (ja) | 2017-09-29 | 2023-07-12 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Ｉｌ－５抗体、その抗原結合フラグメント、およびそれらの医薬適用 |
| CN113507938B (zh) | 2019-03-29 | 2024-04-16 | 广东恒瑞医药有限公司 | 包含抗il-5抗体的药物组合物及其用途 |
| EP3965815A4 (en) | 2019-05-10 | 2023-05-31 | Société des Produits Nestlé S.A. | METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT |
| TW202126688A (zh) * | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| EP3957308A1 (en) * | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ291039B6 (cs) | 1992-02-06 | 2002-12-11 | Schering Corporation | Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek |
| USRE39548E1 (en) | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
| US6056957A (en) | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| BRPI0910854A2 (pt) | 2008-03-28 | 2015-10-06 | Glaxosmithkline Llc | métodos de tratamento |
| WO2011156000A2 (en) * | 2010-06-07 | 2011-12-15 | Aerovance, Inc. | Use of il-4/il-13 antagonists to treat eosinophilic disorders |
| BR112013013460A8 (pt) | 2010-12-16 | 2019-02-12 | Genentech Inc | métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total |
-
2015
- 2015-08-28 KR KR1020177009565A patent/KR102495432B1/ko active IP Right Grant
- 2015-08-28 RS RS20200977A patent/RS60701B1/sr unknown
- 2015-08-28 CA CA2962944A patent/CA2962944A1/en not_active Abandoned
- 2015-08-28 EA EA201790563A patent/EA034864B1/ru not_active IP Right Cessation
- 2015-08-28 PL PL15760590T patent/PL3191513T3/pl unknown
- 2015-08-28 US US14/838,503 patent/US9815894B2/en active Active
- 2015-08-28 EP EP15760590.8A patent/EP3191513B1/en active Active
- 2015-08-28 ES ES15760590T patent/ES2811124T3/es active Active
- 2015-08-28 HU HUE15760590A patent/HUE050202T2/hu unknown
- 2015-08-28 UA UAA201703334A patent/UA122670C2/uk unknown
- 2015-08-28 PT PT157605908T patent/PT3191513T/pt unknown
- 2015-08-28 SI SI201531319T patent/SI3191513T1/sl unknown
- 2015-08-28 AU AU2015315628A patent/AU2015315628A1/en not_active Abandoned
- 2015-08-28 WO PCT/US2015/047357 patent/WO2016040007A1/en active Application Filing
- 2015-08-28 CN CN201580056209.2A patent/CN107073114B/zh active Active
- 2015-08-28 DK DK15760590.8T patent/DK3191513T3/da active
-
2017
- 2017-03-30 ZA ZA2017/02247A patent/ZA201702247B/en unknown
- 2017-10-13 US US15/783,289 patent/US10577414B2/en active Active
-
2020
- 2020-08-17 CY CY20201100764T patent/CY1123501T1/el unknown
- 2020-08-20 HR HRP20201307TT patent/HRP20201307T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160102144A1 (en) | 2016-04-14 |
| ES2811124T3 (es) | 2021-03-10 |
| AU2015315628A1 (en) | 2017-04-20 |
| HUE050202T2 (hu) | 2020-11-30 |
| US20180030131A1 (en) | 2018-02-01 |
| PT3191513T (pt) | 2020-07-31 |
| RS60701B1 (sr) | 2020-09-30 |
| EP3191513A1 (en) | 2017-07-19 |
| US9815894B2 (en) | 2017-11-14 |
| CN107073114B (zh) | 2022-01-14 |
| DK3191513T3 (da) | 2020-08-24 |
| WO2016040007A1 (en) | 2016-03-17 |
| CA2962944A1 (en) | 2016-03-17 |
| CN107073114A (zh) | 2017-08-18 |
| EP3191513B1 (en) | 2020-06-24 |
| KR102495432B1 (ko) | 2023-02-03 |
| EA201790563A1 (ru) | 2017-08-31 |
| KR20170072197A (ko) | 2017-06-26 |
| UA122670C2 (uk) | 2020-12-28 |
| PL3191513T3 (pl) | 2021-02-08 |
| US10577414B2 (en) | 2020-03-03 |
| EA034864B1 (ru) | 2020-03-31 |
| SI3191513T1 (sl) | 2020-12-31 |
| NZ730541A (en) | 2023-10-27 |
| ZA201702247B (en) | 2018-08-29 |
| CY1123501T1 (el) | 2022-03-24 |
| EA201790563A8 (ru) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201307T1 (hr) | Upotreba reslizumaba za liječenje umjerene do ozbiljne eozinofilne astme | |
| MY188749A (en) | Compositions comprising a combination of nivolumab and ipilimumab | |
| HRP20210406T1 (hr) | Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba | |
| MX2019003685A (es) | Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer. | |
| Alten et al. | Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approaches | |
| Luqmani | Discontinuation of therapies in vasculitis | |
| Santiago et al. | Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis. | |
| NZ760155A (en) | 15.beta.-[3-propanamido]-substituted estra-1,3,5 | |
| JP2015517534A5 (hr) | ||
| MX2019000312A (es) | Composicion farmaceutica sinergica de aceclofenaco y betametasona para el tratamiento del dolor de afecciones reumaticas o dolor postquirurgico. | |
| JP2016527322A5 (hr) | ||
| AR089839A1 (es) | Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular | |
| Xu et al. | Subcutaneous administration of bortezomib significantly decreased and delayed the development of peripheral neuropathy in patients with newly diagnosed multiple myeloma | |
| O'Byrne et al. | B21 TRANSLATIONAL ASTHMA RESEARCH: Efficacy And Safety Of A Cxcr2 Antagonist, Azd5069, In Severe, Uncontrolled Persistent Asthma | |
| Gelb et al. | Long-term efficacy and safety of twice-daily aclidinium bromide in COPD patients: a one-year study | |
| Calverley et al. | D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Impact Of A Long-Acting Beta Agonist And An Inhaled Corticosteroid In COPD Patients With Moderate Airflow Obstruction And Cv Disease Or Risk: A Factorial Analysis Of The Summit Trial | |
| WO2016154143A8 (en) | Compositions and methods for treating copd and other inflammatory conditions | |
| Paone et al. | D37 COPD: DEVELOPMENTAL THERAPEUTICS: Frequency Of Exacerbations In Chronic Obstructive Pulmonary Disease: The Efficacy Of Carbocysteine Lysine Salt With Or Without Inhaled Steroids | |
| Matsuo | Various toxicities: case report | |
| Singh et al. | TRIPHALA GUGGULU | |
| Sadigov et al. | B93 BREATHE ANOTHER DAY: UPDATE IN BRONCHIECTASIS: Bronchiectasis In Patients With Severe COPD: How We Can Improve The Clinical Features Of Comorbidities? | |
| 정미혜 et al. | First-line targeted treatment for radioactive iodine-refractory metastatic thyroid cancer | |
| 임기준 et al. | S-616: Abiraterone-associated Severe neutropenia in a Patient with non-severe aplastic anemia | |
| Scuri et al. | Effects Of Extrafine Single Inhaler Triple Therapy On Lung Function In COPD Patients: Results From Responder Analysis From The Trinity Study | |
| Cudzilo et al. | B40 CASE REPORTS: PLEURAL DISEASE AND MALIGNANCY: Methotrexate-Induced Pleuropericarditis And Eosinophilic Pleural Effusion In A Patient With Psoriatic Arthritis |